GenWay Biotech launches multiple biomarker test for myocardial infarction

Testing for multiple biomarkers can improve the sensitivity and accuracy of predictive tests, and GenWay Biotech has created and launched a three-biomarker test--called PREvent--which is designed to help primary care physicians and cardiologists to predict the near term (two- to three-year) risk of heart attack in patients with coronary artery disease. The company presented data on the test at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida. In a study of around 3000 people with suspected or confirmed coronary artery disease, the test identified the top 10% of patients with confirmed coronary artery disease who were six-and-a-half times more likely to have a heart attack within three years, and was 12 times more powerful than the single biomarker CRP. Release | Abstract

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.